Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (22)

Search Parameters:
Keywords = J. Z. Smith

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
16 pages, 1178 KiB  
Article
Venous Resection During Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma—A Multicentre Propensity Score Matching Analysis of the Recurrence After Whipple’s (RAW) Study
by Ruben Bellotti, Somaiah Aroori, Benno Cardini, Florian Ponholzer, Thomas B. Russell, Peter L. Labib, Stefan Schneeberger, Fabio Ausania, Elizabeth Pando, Keith J. Roberts, Ambareen Kausar, Vasileios K. Mavroeidis, Gabriele Marangoni, Sarah C. Thomasset, Adam E. Frampton, Pavlos Lykoudis, Nassir Alhaboob, Hassaan Bari, Andrew M. Smith, Duncan Spalding, Parthi Srinivasan, Brian R. Davidson, Ricky H. Bhogal, Daniel Croagh, Ismael Dominguez, Rohan Thakkar, Dhanny Gomez, Michael A. Silva, Pierfrancesco Lapolla, Andrea Mingoli, Alberto Porcu, Nehal S. Shah, Zaed Z. R. Hamady, Bilal Al-Sarrieh, Alejandro Serrablo, RAW Study Collaborators and Manuel Maglioneadd Show full author list remove Hide full author list
Cancers 2025, 17(7), 1223; https://doi.org/10.3390/cancers17071223 - 4 Apr 2025
Viewed by 964
Abstract
Background: Pancreatoduodenectomy with venous resection (PDVR) may be performed to achieve tumour clearance in patients with a pancreatic ductal adenocarcinoma (PDAC) with venous involvement. This study aimed to evaluate the impact of PDVR on PDAC outcomes. Methods: In total, 435 PDAC [...] Read more.
Background: Pancreatoduodenectomy with venous resection (PDVR) may be performed to achieve tumour clearance in patients with a pancreatic ductal adenocarcinoma (PDAC) with venous involvement. This study aimed to evaluate the impact of PDVR on PDAC outcomes. Methods: In total, 435 PDAC patients with either R0 status (n = 322) or R1 status within the superior mesenteric vein groove (n = 113) were extracted from the Recurrence After Whipple’s (RAW) study dataset. PDVR patients were matched in a 1:2 ratio with standard PD patients. Comparisons were then made between the two groups (surgical radicality and survival). Results: A total of 81 PDVRs were matched with 162 PDs. Neoadjuvant chemotherapy (5.7% vs. 13.6%, p = 0.032) and R1 resection rates (17.9% vs. 42%, p < 0.001) were higher in the PDVR group. Risk factors for R1 resection included venous resection (p < 0.001 for sleeve and p = 0.034 for segmental resection), pT3 (p = 0.007), and pN1 stage (p = 0.045). PDVR patients had lower median overall survival (OS, 21 vs. 30 months (m), p = 0.023) and disease-free survival (DFS, 17 m vs. 24 m, p = 0.043). Among PDVR patients, R status did not impact on OS (R0: 23 m, R1: 21 m, p = 0.928) or DFS (R0: 18 m, R1: 17 m, p = 0.558). Irrespective of R status, systemic recurrence was higher in the PDVR group (p = 0.034). Conclusions: Independent of R status, the PDVR group had lower overall survival and higher systemic recurrence rates. Full article
(This article belongs to the Special Issue Surgical Oncology for Hepato-Pancreato-Biliary Cancer)
Show Figures

Graphical abstract

7 pages, 645 KiB  
Communication
Evaluating the Effect of Body Mass Index on Procalcitonin Level in Patients with Pneumonia: A Retrospective Cross-Sectional Study
by Mohammad Z. Khrais, J. Curran Henson, Jake Smith and Nikhil Meena
Adv. Respir. Med. 2025, 93(1), 1; https://doi.org/10.3390/arm93010001 - 26 Jan 2025
Viewed by 898
Abstract
Procalcitonin (PCT) is commonly used to evaluate the etiology and severity of pneumonia. PCT has been shown to be elevated at baseline in patients with obesity. The aim of this study is to determine if body mass index (BMI) has an influence on [...] Read more.
Procalcitonin (PCT) is commonly used to evaluate the etiology and severity of pneumonia. PCT has been shown to be elevated at baseline in patients with obesity. The aim of this study is to determine if body mass index (BMI) has an influence on admission PCT level in patients admitted to the hospital with a diagnosis of pneumonia. We conducted a retrospective cohort study that encompassed patient visits to a tertiary care center from 2014 until September 2023. A total of 18,652 patients presented to the emergency department with a diagnosis of pneumonia. A total of 3659 were admitted to the floor, and 2246 were admitted to the MICU. Patients were grouped based on admission BMI into five categories. The Kruskal–Wallis test performed on patients admitted to the floor revealed a statistically significant difference in PCT levels among groups of different BMIs (H = 34.97, df = 4, p < 0.001). In patients admitted to the MICU, the Kruskal–Wallis test revealed a significant difference in PCT levels among groups of different BMIs (H = 32.92, df = 4, p < 0.001). BMI has a statistically significant effect on PCT in patients admitted to the hospital with pneumonia. Patients with higher BMI may exhibit less robust PCT levels, which may impact management decisions. Full article
Show Figures

Figure 1

45 pages, 30346 KiB  
Article
Performance of a Modular Ton-Scale Pixel-Readout Liquid Argon Time Projection Chamber
by A. Abed Abud, B. Abi, R. Acciarri, M. A. Acero, M. R. Adames, G. Adamov, M. Adamowski, D. Adams, M. Adinolfi, C. Adriano, A. Aduszkiewicz, J. Aguilar, B. Aimard, F. Akbar, K. Allison, S. Alonso Monsalve, M. Alrashed, A. Alton, R. Alvarez, T. Alves, H. Amar, P. Amedo, J. Anderson, D. A. Andrade, C. Andreopoulos, M. Andreotti, M. P. Andrews, F. Andrianala, S. Andringa, N. Anfimov, A. Ankowski, M. Antoniassi, M. Antonova, A. Antoshkin, A. Aranda-Fernandez, L. Arellano, E. Arrieta Diaz, M. A. Arroyave, J. Asaadi, A. Ashkenazi, D. Asner, L. Asquith, E. Atkin, D. Auguste, A. Aurisano, V. Aushev, D. Autiero, F. Azfar, A. Back, H. Back, J. J. Back, I. Bagaturia, L. Bagby, N. Balashov, S. Balasubramanian, P. Baldi, W. Baldini, J. Baldonedo, B. Baller, B. Bambah, R. Banerjee, F. Barao, G. Barenboim, P. B̃arham Alzás, G. J. Barker, W. Barkhouse, G. Barr, J. Barranco Monarca, A. Barros, N. Barros, D. Barrow, J. L. Barrow, A. Basharina-Freshville, A. Bashyal, V. Basque, C. Batchelor, L. Bathe-Peters, J. B. R. Battat, F. Battisti, F. Bay, M. C. Q. Bazetto, J. L. L. Bazo Alba, J. F. Beacom, E. Bechetoille, B. Behera, E. Belchior, G. Bell, L. Bellantoni, G. Bellettini, V. Bellini, O. Beltramello, N. Benekos, C. Benitez Montiel, D. Benjamin, F. Bento Neves, J. Berger, S. Berkman, J. Bernal, P. Bernardini, A. Bersani, S. Bertolucci, M. Betancourt, A. Betancur Rodríguez, A. Bevan, Y. Bezawada, A. T. Bezerra, T. J. Bezerra, A. Bhat, V. Bhatnagar, J. Bhatt, M. Bhattacharjee, M. Bhattacharya, S. Bhuller, B. Bhuyan, S. Biagi, J. Bian, K. Biery, B. Bilki, M. Bishai, A. Bitadze, A. Blake, F. D. Blaszczyk, G. C. Blazey, E. Blucher, J. Bogenschuetz, J. Boissevain, S. Bolognesi, T. Bolton, L. Bomben, M. Bonesini, C. Bonilla-Diaz, F. Bonini, A. Booth, F. Boran, S. Bordoni, R. Borges Merlo, A. Borkum, N. Bostan, J. Bracinik, D. Braga, B. Brahma, D. Brailsford, F. Bramati, A. Branca, A. Brandt, J. Bremer, C. Brew, S. J. Brice, V. Brio, C. Brizzolari, C. Bromberg, J. Brooke, A. Bross, G. Brunetti, M. Brunetti, N. Buchanan, H. Budd, J. Buergi, D. Burgardt, S. Butchart, G. Caceres V., I. Cagnoli, T. Cai, R. Calabrese, J. Calcutt, M. Calin, L. Calivers, E. Calvo, A. Caminata, A. F. Camino, W. Campanelli, A. Campani, A. Campos Benitez, N. Canci, J. Capó, I. Caracas, D. Caratelli, D. Carber, J. M. Carceller, G. Carini, B. Carlus, M. F. Carneiro, P. Carniti, I. Caro Terrazas, H. Carranza, N. Carrara, L. Carroll, T. Carroll, A. Carter, E. Casarejos, D. Casazza, J. F. Castaño Forero, F. A. Castaño, A. Castillo, C. Castromonte, E. Catano-Mur, C. Cattadori, F. Cavalier, F. Cavanna, S. Centro, G. Cerati, C. Cerna, A. Cervelli, A. Cervera Villanueva, K. Chakraborty, S. Chakraborty, M. Chalifour, A. Chappell, N. Charitonidis, A. Chatterjee, H. Chen, M. Chen, W. C. Chen, Y. Chen, Z. Chen-Wishart, D. Cherdack, C. Chi, R. Chirco, N. Chitirasreemadam, K. Cho, S. Choate, D. Chokheli, P. S. Chong, B. Chowdhury, D. Christian, A. Chukanov, M. Chung, E. Church, M. F. Cicala, M. Cicerchia, V. Cicero, R. Ciolini, P. Clarke, G. Cline, T. E. Coan, A. G. Cocco, J. A. B. Coelho, A. Cohen, J. Collazo, J. Collot, E. Conley, J. M. Conrad, M. Convery, S. Copello, P. Cova, C. Cox, L. Cremaldi, L. Cremonesi, J. I. Crespo-Anadón, M. Crisler, E. Cristaldo, J. Crnkovic, G. Crone, R. Cross, A. Cudd, C. Cuesta, Y. Cui, F. Curciarello, D. Cussans, J. Dai, O. Dalager, R. Dallavalle, W. Dallaway, H. da Motta, Z. A. Dar, R. Darby, L. Da Silva Peres, Q. David, G. S. Davies, S. Davini, J. Dawson, R. De Aguiar, P. De Almeida, P. Debbins, I. De Bonis, M. P. Decowski, A. de Gouvêa, P. C. De Holanda, I. L. De Icaza Astiz, P. De Jong, P. Del Amo Sanchez, A. De la Torre, G. De Lauretis, A. Delbart, D. Delepine, M. Delgado, A. Dell’Acqua, G. Delle Monache, N. Delmonte, P. De Lurgio, R. Demario, G. De Matteis, J. R. T. de Mello Neto, D. M. DeMuth, S. Dennis, C. Densham, P. Denton, G. W. Deptuch, A. De Roeck, V. De Romeri, J. P. Detje, J. Devine, R. Dharmapalan, M. Dias, A. Diaz, J. S. Díaz, F. Díaz, F. Di Capua, A. Di Domenico, S. Di Domizio, S. Di Falco, L. Di Giulio, P. Ding, L. Di Noto, E. Diociaiuti, C. Distefano, R. Diurba, M. Diwan, Z. Djurcic, D. Doering, S. Dolan, F. Dolek, M. J. Dolinski, D. Domenici, L. Domine, S. Donati, Y. Donon, S. Doran, D. Douglas, T. A. Doyle, A. Dragone, F. Drielsma, L. Duarte, D. Duchesneau, K. Duffy, K. Dugas, P. Dunne, B. Dutta, H. Duyang, D. A. Dwyer, A. S. Dyshkant, S. Dytman, M. Eads, A. Earle, S. Edayath, D. Edmunds, J. Eisch, P. Englezos, A. Ereditato, T. Erjavec, C. O. Escobar, J. J. Evans, E. Ewart, A. C. Ezeribe, K. Fahey, L. Fajt, A. Falcone, M. Fani’, C. Farnese, S. Farrell, Y. Farzan, D. Fedoseev, J. Felix, Y. Feng, E. Fernandez-Martinez, G. Ferry, L. Fields, P. Filip, A. Filkins, F. Filthaut, R. Fine, G. Fiorillo, M. Fiorini, S. Fogarty, W. Foreman, J. Fowler, J. Franc, K. Francis, D. Franco, J. Franklin, J. Freeman, J. Fried, A. Friedland, S. Fuess, I. K. Furic, K. Furman, A. P. Furmanski, R. Gaba, A. Gabrielli, A. M. Gago, F. Galizzi, H. Gallagher, A. Gallas, N. Gallice, V. Galymov, E. Gamberini, T. Gamble, F. Ganacim, R. Gandhi, S. Ganguly, F. Gao, S. Gao, D. Garcia-Gamez, M. Á. García-Peris, F. Gardim, S. Gardiner, D. Gastler, A. Gauch, J. Gauvreau, P. Gauzzi, S. Gazzana, G. Ge, N. Geffroy, B. Gelli, S. Gent, L. Gerlach, Z. Ghorbani-Moghaddam, T. Giammaria, D. Gibin, I. Gil-Botella, S. Gilligan, A. Gioiosa, S. Giovannella, C. Girerd, A. K. Giri, C. Giugliano, V. Giusti, D. Gnani, O. Gogota, S. Gollapinni, K. Gollwitzer, R. A. Gomes, L. V. Gomez Bermeo, L. S. Gomez Fajardo, F. Gonnella, D. Gonzalez-Diaz, M. Gonzalez-Lopez, M. C. Goodman, S. Goswami, C. Gotti, J. Goudeau, E. Goudzovski, C. Grace, E. Gramellini, R. Gran, E. Granados, P. Granger, C. Grant, D. R. Gratieri, G. Grauso, P. Green, S. Greenberg, J. Greer, W. C. Griffith, F. T. Groetschla, K. Grzelak, L. Gu, W. Gu, V. Guarino, M. Guarise, R. Guenette, E. Guerard, M. Guerzoni, D. Guffanti, A. Guglielmi, B. Guo, Y. Guo, A. Gupta, V. Gupta, G. Gurung, D. Gutierrez, P. Guzowski, M. M. Guzzo, S. Gwon, A. Habig, H. Hadavand, L. Haegel, R. Haenni, L. Hagaman, A. Hahn, J. Haiston, J. Hakenmueller, T. Hamernik, P. Hamilton, J. Hancock, F. Happacher, D. A. Harris, J. Hartnell, T. Hartnett, J. Harton, T. Hasegawa, C. Hasnip, R. Hatcher, K. Hayrapetyan, J. Hays, E. Hazen, M. He, A. Heavey, K. M. Heeger, J. Heise, S. Henry, M. A. Hernandez Morquecho, K. Herner, V. Hewes, A. Higuera, C. Hilgenberg, S. J. Hillier, A. Himmel, E. Hinkle, L. R. Hirsch, J. Ho, J. Hoff, A. Holin, T. Holvey, E. Hoppe, S. Horiuchi, G. A. Horton-Smith, M. Hostert, T. Houdy, B. Howard, R. Howell, I. Hristova, M. S. Hronek, J. Huang, R. G. Huang, Z. Hulcher, M. Ibrahim, G. Iles, N. Ilic, A. M. Iliescu, R. Illingworth, G. Ingratta, A. Ioannisian, B. Irwin, L. Isenhower, M. Ismerio Oliveira, R. Itay, C. M. Jackson, V. Jain, E. James, W. Jang, B. Jargowsky, D. Jena, I. Jentz, X. Ji, C. Jiang, J. Jiang, L. Jiang, A. Jipa, F. R. Joaquim, W. Johnson, C. Jollet, B. Jones, R. Jones, D. José Fernández, N. Jovancevic, M. Judah, C. K. Jung, T. Junk, Y. Jwa, M. Kabirnezhad, A. C. Kaboth, I. Kadenko, I. Kakorin, A. Kalitkina, D. Kalra, M. Kandemir, D. M. Kaplan, G. Karagiorgi, G. Karaman, A. Karcher, Y. Karyotakis, S. Kasai, S. P. Kasetti, L. Kashur, I. Katsioulas, A. Kauther, N. Kazaryan, L. Ke, E. Kearns, P. T. Keener, K. J. Kelly, E. Kemp, O. Kemularia, Y. Kermaidic, W. Ketchum, S. H. Kettell, M. Khabibullin, N. Khan, A. Khvedelidze, D. Kim, J. Kim, M. Kim, B. King, B. Kirby, M. Kirby, A. Kish, J. Klein, J. Kleykamp, A. Klustova, T. Kobilarcik, L. Koch, K. Koehler, L. W. Koerner, D. H. Koh, L. Kolupaeva, D. Korablev, M. Kordosky, T. Kosc, U. Kose, V. A. Kostelecký, K. Kothekar, I. Kotler, M. Kovalcuk, V. Kozhukalov, W. Krah, R. Kralik, M. Kramer, L. Kreczko, F. Krennrich, I. Kreslo, T. Kroupova, S. Kubota, M. Kubu, Y. Kudenko, V. A. Kudryavtsev, G. Kufatty, S. Kuhlmann, J. Kumar, P. Kumar, S. Kumaran, P. Kunze, J. Kunzmann, R. Kuravi, N. Kurita, C. Kuruppu, V. Kus, T. Kutter, J. Kvasnicka, T. Labree, T. Lackey, A. Lambert, B. J. Land, C. E. Lane, N. Lane, K. Lang, T. Langford, M. Langstaff, F. Lanni, O. Lantwin, J. Larkin, P. Lasorak, D. Last, A. Laudrain, A. Laundrie, G. Laurenti, E. Lavaut, A. Lawrence, P. Laycock, I. Lazanu, M. Lazzaroni, T. Le, S. Leardini, J. Learned, T. LeCompte, C. Lee, V. Legin, G. Lehmann Miotto, R. Lehnert, M. A. Leigui de Oliveira, M. Leitner, D. Leon Silverio, L. M. Lepin, J.-Y. Li, S. W. Li, Y. Li, H. Liao, C. S. Lin, D. Lindebaum, S. Linden, R. A. Lineros, J. Ling, A. Lister, B. R. Littlejohn, H. Liu, J. Liu, Y. Liu, S. Lockwitz, M. Lokajicek, I. Lomidze, K. Long, T. V. Lopes, J. Lopez, I. López de Rego, N. López-March, T. Lord, J. M. LoSecco, W. C. Louis, A. Lozano Sanchez, X.-G. Lu, K. B. Luk, B. Lunday, X. Luo, E. Luppi, J. Maalmi, D. MacFarlane, A. A. Machado, P. Machado, C. T. Macias, J. R. Macier, M. MacMahon, A. Maddalena, A. Madera, P. Madigan, S. Magill, C. Magueur, K. Mahn, A. Maio, A. Major, K. Majumdar, M. Man, R. C. Mandujano, J. Maneira, S. Manly, A. Mann, K. Manolopoulos, M. Manrique Plata, S. Manthey Corchado, V. N. Manyam, M. Marchan, A. Marchionni, W. Marciano, D. Marfatia, C. Mariani, J. Maricic, F. Marinho, A. D. Marino, T. Markiewicz, F. Das Chagas Marques, C. Marquet, D. Marsden, M. Marshak, C. M. Marshall, J. Marshall, L. Martina, J. Martín-Albo, N. Martinez, D. A. Martinez Caicedo, F. Martínez López, P. Martínez Miravé, S. Martynenko, V. Mascagna, C. Massari, A. Mastbaum, F. Matichard, S. Matsuno, G. Matteucci, J. Matthews, C. Mauger, N. Mauri, K. Mavrokoridis, I. Mawby, R. Mazza, A. Mazzacane, T. McAskill, N. McConkey, K. S. McFarland, C. McGrew, A. McNab, L. Meazza, V. C. N. Meddage, B. Mehta, P. Mehta, P. Melas, O. Mena, H. Mendez, P. Mendez, D. P. Méndez, A. Menegolli, G. Meng, A. C. E. A. Mercuri, A. Meregaglia, M. D. Messier, S. Metallo, J. Metcalf, W. Metcalf, M. Mewes, H. Meyer, T. Miao, A. Miccoli, G. Michna, V. Mikola, R. Milincic, F. Miller, G. Miller, W. Miller, O. Mineev, A. Minotti, L. Miralles, O. G. Miranda, C. Mironov, S. Miryala, S. Miscetti, C. S. Mishra, S. R. Mishra, A. Mislivec, M. Mitchell, D. Mladenov, I. Mocioiu, A. Mogan, N. Moggi, R. Mohanta, T. A. Mohayai, N. Mokhov, J. Molina, L. Molina Bueno, E. Montagna, A. Montanari, C. Montanari, D. Montanari, D. Montanino, L. M. Montaño Zetina, M. Mooney, A. F. Moor, Z. Moore, D. Moreno, O. Moreno-Palacios, L. Morescalchi, D. Moretti, R. Moretti, C. Morris, C. Mossey, M. Mote, C. A. Moura, G. Mouster, W. Mu, L. Mualem, J. Mueller, M. Muether, F. Muheim, A. Muir, M. Mulhearn, D. Munford, L. J. Munteanu, H. Muramatsu, J. Muraz, M. Murphy, T. Murphy, J. Muse, A. Mytilinaki, J. Nachtman, Y. Nagai, S. Nagu, R. Nandakumar, D. Naples, S. Narita, A. Nath, A. Navrer-Agasson, N. Nayak, M. Nebot-Guinot, A. Nehm, J. K. Nelson, O. Neogi, J. Nesbit, M. Nessi, D. Newbold, M. Newcomer, R. Nichol, F. Nicolas-Arnaldos, A. Nikolica, J. Nikolov, E. Niner, K. Nishimura, A. Norman, A. Norrick, P. Novella, J. A. Nowak, M. Oberling, J. P. Ochoa-Ricoux, S. Oh, S. B. Oh, A. Olivier, A. Olshevskiy, T. Olson, Y. Onel, Y. Onishchuk, A. Oranday, M. Osbiston, J. A. Osorio Vélez, L. Otiniano Ormachea, J. Ott, L. Pagani, G. Palacio, O. Palamara, S. Palestini, J. M. Paley, M. Pallavicini, C. Palomares, S. Pan, P. Panda, W. Panduro Vazquez, E. Pantic, V. Paolone, V. Papadimitriou, R. Papaleo, A. Papanestis, D. Papoulias, S. Paramesvaran, A. Paris, S. Parke, E. Parozzi, S. Parsa, Z. Parsa, S. Parveen, M. Parvu, D. Pasciuto, S. Pascoli, L. Pasqualini, J. Pasternak, C. Patrick, L. Patrizii, R. B. Patterson, T. Patzak, A. Paudel, L. Paulucci, Z. Pavlovic, G. Pawloski, D. Payne, V. Pec, E. Pedreschi, S. J. M. Peeters, W. Pellico, A. Pena Perez, E. Pennacchio, A. Penzo, O. L. G. Peres, Y. F. Perez Gonzalez, L. Pérez-Molina, C. Pernas, J. Perry, D. Pershey, G. Pessina, G. Petrillo, C. Petta, R. Petti, M. Pfaff, V. Pia, L. Pickering, F. Pietropaolo, V. L. Pimentel, G. Pinaroli, J. Pinchault, K. Pitts, K. Plows, R. Plunkett, C. Pollack, T. Pollman, D. Polo-Toledo, F. Pompa, X. Pons, N. Poonthottathil, V. Popov, F. Poppi, J. Porter, M. Potekhin, R. Potenza, J. Pozimski, M. Pozzato, T. Prakash, C. Pratt, M. Prest, F. Psihas, D. Pugnere, X. Qian, J. L. Raaf, V. Radeka, J. Rademacker, B. Radics, A. Rafique, E. Raguzin, M. Rai, S. Rajagopalan, M. Rajaoalisoa, I. Rakhno, L. Rakotondravohitra, L. Ralte, M. A. Ramirez Delgado, B. Ramson, A. Rappoldi, G. Raselli, P. Ratoff, R. Ray, H. Razafinime, E. M. Rea, J. S. Real, B. Rebel, R. Rechenmacher, M. Reggiani-Guzzo, J. Reichenbacher, S. D. Reitzner, H. Rejeb Sfar, E. Renner, A. Renshaw, S. Rescia, F. Resnati, D. Restrepo, C. Reynolds, M. Ribas, S. Riboldi, C. Riccio, G. Riccobene, J. S. Ricol, M. Rigan, E. V. Rincón, A. Ritchie-Yates, S. Ritter, D. Rivera, R. Rivera, A. Robert, J. L. Rocabado Rocha, L. Rochester, M. Roda, P. Rodrigues, M. J. Rodriguez Alonso, J. Rodriguez Rondon, S. Rosauro-Alcaraz, P. Rosier, D. Ross, M. Rossella, M. Rossi, M. Ross-Lonergan, N. Roy, P. Roy, C. Rubbia, A. Ruggeri, G. Ruiz Ferreira, B. Russell, D. Ruterbories, A. Rybnikov, A. Saa-Hernandez, R. Saakyan, S. Sacerdoti, S. K. Sahoo, N. Sahu, P. Sala, N. Samios, O. Samoylov, M. C. Sanchez, A. Sánchez Bravo, P. Sanchez-Lucas, V. Sandberg, D. A. Sanders, S. Sanfilippo, D. Sankey, D. Santoro, N. Saoulidou, P. Sapienza, C. Sarasty, I. Sarcevic, I. Sarra, G. Savage, V. Savinov, G. Scanavini, A. Scaramelli, A. Scarff, T. Schefke, H. Schellman, S. Schifano, P. Schlabach, D. Schmitz, A. W. Schneider, K. Scholberg, A. Schukraft, B. Schuld, A. Segade, E. Segreto, A. Selyunin, C. R. Senise, J. Sensenig, M. H. Shaevitz, P. Shanahan, P. Sharma, R. Kumar, K. Shaw, T. Shaw, K. Shchablo, J. Shen, C. Shepherd-Themistocleous, A. Sheshukov, W. Shi, S. Shin, S. Shivakoti, I. Shoemaker, D. Shooltz, R. Shrock, B. Siddi, M. Siden, J. Silber, L. Simard, J. Sinclair, G. Sinev, Jaydip Singh, J. Singh, L. Singh, P. Singh, V. Singh, S. Singh Chauhan, R. Sipos, C. Sironneau, G. Sirri, K. Siyeon, K. Skarpaas, J. Smedley, E. Smith, J. Smith, P. Smith, J. Smolik, M. Smy, M. Snape, E. L. Snider, P. Snopok, D. Snowden-Ifft, M. Soares Nunes, H. Sobel, M. Soderberg, S. Sokolov, C. J. Solano Salinas, S. Söldner-Rembold, S. R. Soleti, N. Solomey, V. Solovov, W. E. Sondheim, M. Sorel, A. Sotnikov, J. Soto-Oton, A. Sousa, K. Soustruznik, F. Spinella, J. Spitz, N. J. C. Spooner, K. Spurgeon, D. Stalder, M. Stancari, L. Stanco, J. Steenis, R. Stein, H. M. Steiner, A. F. Steklain Lisbôa, A. Stepanova, J. Stewart, B. Stillwell, J. Stock, F. Stocker, T. Stokes, M. Strait, T. Strauss, L. Strigari, A. Stuart, J. G. Suarez, J. Subash, A. Surdo, L. Suter, C. M. Sutera, K. Sutton, Y. Suvorov, R. Svoboda, S. K. Swain, B. Szczerbinska, A. M. Szelc, A. Sztuc, A. Taffara, N. Talukdar, J. Tamara, H. A. Tanaka, S. Tang, N. Taniuchi, A. M. Tapia Casanova, B. Tapia Oregui, A. Tapper, S. Tariq, E. Tarpara, E. Tatar, R. Tayloe, D. Tedeschi, A. M. Teklu, J. Tena Vidal, P. Tennessen, M. Tenti, K. Terao, F. Terranova, G. Testera, T. Thakore, A. Thea, A. Thiebault, S. Thomas, A. Thompson, C. Thorn, S. C. Timm, E. Tiras, V. Tishchenko, N. Todorović, L. Tomassetti, A. Tonazzo, D. Torbunov, M. Torti, M. Tortola, F. Tortorici, N. Tosi, D. Totani, M. Toups, C. Touramanis, D. Tran, R. Travaglini, J. Trevor, E. Triller, S. Trilov, J. Truchon, D. Truncali, W. H. Trzaska, Y. Tsai, Y.-T. Tsai, Z. Tsamalaidze, K. V. Tsang, N. Tsverava, S. Z. Tu, S. Tufanli, C. Tunnell, J. Turner, M. Tuzi, J. Tyler, E. Tyley, M. Tzanov, M. A. Uchida, J. Ureña González, J. Urheim, T. Usher, H. Utaegbulam, S. Uzunyan, M. R. Vagins, P. Vahle, S. Valder, G. A. Valdiviesso, E. Valencia, R. Valentim, Z. Vallari, E. Vallazza, J. W. F. Valle, R. Van Berg, R. G. Van de Water, D. V. Forero, A. Vannozzi, M. Van Nuland-Troost, F. Varanini, D. Vargas Oliva, S. Vasina, N. Vaughan, K. Vaziri, A. Vázquez-Ramos, J. Vega, S. Ventura, A. Verdugo, S. Vergani, M. Verzocchi, K. Vetter, M. Vicenzi, H. Vieira de Souza, C. Vignoli, C. Vilela, E. Villa, S. Viola, B. Viren, A. Vizcaya-Hernandez, T. Vrba, Q. Vuong, A. V. Waldron, M. Wallbank, J. Walsh, T. Walton, H. Wang, J. Wang, L. Wang, M. H. L. S. Wang, X. Wang, Y. Wang, K. Warburton, D. Warner, L. Warsame, M. O. Wascko, D. Waters, A. Watson, K. Wawrowska, A. Weber, C. M. Weber, M. Weber, H. Wei, A. Weinstein, H. Wenzel, S. Westerdale, M. Wetstein, K. Whalen, J. Whilhelmi, A. White, A. White, L. H. Whitehead, D. Whittington, M. J. Wilking, A. Wilkinson, C. Wilkinson, F. Wilson, R. J. Wilson, P. Winter, W. Wisniewski, J. Wolcott, J. Wolfs, T. Wongjirad, A. Wood, K. Wood, E. Worcester, M. Worcester, M. Wospakrik, K. Wresilo, C. Wret, S. Wu, W. Wu, W. Wu, M. Wurm, J. Wyenberg, Y. Xiao, I. Xiotidis, B. Yaeggy, N. Yahlali, E. Yandel, K. Yang, T. Yang, A. Yankelevich, N. Yershov, K. Yonehara, T. Young, B. Yu, H. Yu, J. Yu, Y. Yu, W. Yuan, R. Zaki, J. Zalesak, L. Zambelli, B. Zamorano, A. Zani, O. Zapata, L. Zazueta, G. P. Zeller, J. Zennamo, K. Zeug, C. Zhang, S. Zhang, M. Zhao, E. Zhivun, E. D. Zimmerman, S. Zucchelli, J. Zuklin, V. Zutshi, R. Zwaska and on behalf of the DUNE Collaborationadd Show full author list remove Hide full author list
Instruments 2024, 8(3), 41; https://doi.org/10.3390/instruments8030041 - 11 Sep 2024
Cited by 4 | Viewed by 3777
Abstract
The Module-0 Demonstrator is a single-phase 600 kg liquid argon time projection chamber operated as a prototype for the DUNE liquid argon near detector. Based on the ArgonCube design concept, Module-0 features a novel 80k-channel pixelated charge readout and advanced high-coverage photon detection [...] Read more.
The Module-0 Demonstrator is a single-phase 600 kg liquid argon time projection chamber operated as a prototype for the DUNE liquid argon near detector. Based on the ArgonCube design concept, Module-0 features a novel 80k-channel pixelated charge readout and advanced high-coverage photon detection system. In this paper, we present an analysis of an eight-day data set consisting of 25 million cosmic ray events collected in the spring of 2021. We use this sample to demonstrate the imaging performance of the charge and light readout systems as well as the signal correlations between the two. We also report argon purity and detector uniformity measurements and provide comparisons to detector simulations. Full article
Show Figures

Figure 1

15 pages, 3451 KiB  
Article
Natural Prevalence, Molecular Characteristics, and Biological Activity of Metarhizium rileyi (Farlow) Isolated from Spodoptera frugiperda (J. E. Smith) Larvae in Mexico
by Yordanys Ramos, Samuel Pineda-Guillermo, Patricia Tamez-Guerra, Alonso Alberto Orozco-Flores, José Isaac Figueroa de la Rosa, Selene Ramos-Ortiz, Juan Manuel Chavarrieta-Yáñez and Ana Mabel Martínez-Castillo
J. Fungi 2024, 10(6), 416; https://doi.org/10.3390/jof10060416 - 8 Jun 2024
Cited by 1 | Viewed by 1855
Abstract
Entomopathogenic fungi have been considered potential biological control agents against the fall armyworm Spodoptera frugiperda (J. E. Smith), the world’s most important pest of maize. In this study, we evaluated the natural infection, molecular characteristics, and biological activity of Metarhizium rileyi (Farlow) isolated [...] Read more.
Entomopathogenic fungi have been considered potential biological control agents against the fall armyworm Spodoptera frugiperda (J. E. Smith), the world’s most important pest of maize. In this study, we evaluated the natural infection, molecular characteristics, and biological activity of Metarhizium rileyi (Farlow) isolated from S. frugiperda larvae of this insect, collected from maize crops in five Mexican locations. Natural infection ranged from 23% to 90% across all locations analyzed. Twenty-four isolates were evaluated on S. frugiperda second instars at a concentration of 1.0 × 108 conidia/mL, causing 70% to 98.7% mortality and 60.5% to 98.7% sporulation. Isolates T9-21, Z30-21, PP48-21, and L8-22 were selected to determine their phylogenetic relationships by β-tubulin gene analysis and to compare median lethal concentration (CL50), median lethal time (LT50), and larval survival. These isolates were grouped into three clades. The T9-21, PP48-21, and J10-22 isolates were closely related (clade A), but phylogenetically distant from Z30-21 (clade B) and L8-22 (clade C) isolates. These genetic differences were not always reflected in their pathogenicity characteristics since no differences were observed among the LC50 values. Furthermore, isolates T9-21, J10-22, and L8-22 were the fastest to kill S. frugiperda larvae, causing lower survival rates. We conclude that native M. rileyi isolates represent an important alternative for the biocontrol of S. frugiperda. Full article
(This article belongs to the Section Fungal Pathogenesis and Disease Control)
Show Figures

Figure 1

16 pages, 550 KiB  
Systematic Review
Helpful, Unnecessary, or Harmful: A Systematic Review of the Effects of Prescription Drug Monitoring Program Use on Opioid Prescriptions
by Nina Z. Y. Smith, J. Douglas Thornton, Susan H. Fenton, Debora Simmons and Tiffany Champagne-Langabeer
Pharmacoepidemiology 2023, 2(4), 350-365; https://doi.org/10.3390/pharma2040030 - 15 Dec 2023
Cited by 3 | Viewed by 5117
Abstract
Prescription drug misuse is a global problem, especially in the United States (US). Clinician involvement is necessary in this crisis, and prescription drug monitoring programs (PDMPs) are a recommended tool for the prevention, recognition, and management of prescription opioid misuse. However, because of [...] Read more.
Prescription drug misuse is a global problem, especially in the United States (US). Clinician involvement is necessary in this crisis, and prescription drug monitoring programs (PDMPs) are a recommended tool for the prevention, recognition, and management of prescription opioid misuse. However, because of the plethora of differences between different PDMPs, research on their effects is mixed. Yet, despite varied evidence, policy on PDMP use is trending stricter and more comprehensive. We aimed to identify patterns in the research to inform clinicians and policy. Through a systematic review of four literature databases (CINAHL, Cochrane Database, Embase, and Medline/OVID), we found 56 experimental and quasi-experimental studies published between 2016 and 2023 evaluating PDMP effects on clinician behavior. To address study heterogeneity, we categorized studies by type of intervention and study outcome. The review suggests that more comprehensive PDMP legislation is associated with decreases in the number of opioid prescriptions overall and the number of risky prescriptions prescribed or dispensed. However, this review shows that much is still unknown, encourages improvements to PDMPs and policies, and suggests further research. Full article
(This article belongs to the Special Issue Pharmacoepidemiology and Addiction)
Show Figures

Figure 1

11 pages, 847 KiB  
Article
Field Test of the Propheromones of the Whitemarked Tussock Moth (WMTM) Orgyia leucostigma (J.E. Smith) (Lepidoptera: Erebidae)
by Peter Mayo, Sumudu Deepa Abeysekera, Peter J. Silk, David I. MaGee, Gaetan Leclair, Jon Sweeney and Jeffrey Ogden
Insects 2023, 14(11), 880; https://doi.org/10.3390/insects14110880 - 15 Nov 2023
Viewed by 1364
Abstract
The whitemarked tussock moth (WMTM), Orgyia leucostigma (J.E. Smith) (Lepidoptera: Erebidae), is an economic pest in Nova Scotia, Canada, where it undergoes periodic outbreaks defoliating several tree species of economic value, including balsam fir, Abies balsamea (L.) Miller (Pinaceae). Herein is described a [...] Read more.
The whitemarked tussock moth (WMTM), Orgyia leucostigma (J.E. Smith) (Lepidoptera: Erebidae), is an economic pest in Nova Scotia, Canada, where it undergoes periodic outbreaks defoliating several tree species of economic value, including balsam fir, Abies balsamea (L.) Miller (Pinaceae). Herein is described a releasing device for the WMTM sex pheromone (Z,Z)-6, 9-heneicosadien-11-one based on a rubber septum, which converts pheromone precursors, such as acetals, namely (Z,Z)-11,11-dimethoxy-6,9-heneicosadiene and (Z,Z)-6,9-heneicosadien-11-one ethylene ketal, to the pheromone itself by the action of acetic acid and releases it over time. The pheromone is unstable in nature and, consequently, lures made with this compound will only attract WMTM for a day or two. The two pheromone precursors, however, are more stable, and are converted slowly into the pheromone by acetic acid impregnated in the releasing device, or by acidic conditions in the environment. The two pheromone precursors were synthesized in 2019 using a modified, previously published approach. Field trapping studies conducted from 2019–22 showed that traps baited with rubber septa loaded with either (Z,Z)-11,11-dimethoxy-6,9-heneicosadiene by itself or (Z,Z)-6,9-heneicosadien-11-one ethylene ketal plus acetic acid consistently caught significantly more WMTM than traps baited with blank septa in most experiments. Full article
Show Figures

Figure 1

15 pages, 4235 KiB  
Article
Extract of Artemisia dracunculus L. Modulates Osteoblast Proliferation and Mineralization
by Matthew C. Scott, Aleah Bourgeois, Yongmei Yu, David H. Burk, Brenda J. Smith and Z. Elizabeth Floyd
Int. J. Mol. Sci. 2023, 24(17), 13423; https://doi.org/10.3390/ijms241713423 - 30 Aug 2023
Cited by 7 | Viewed by 1838
Abstract
Thiazolidinediones (TZD) significantly improve insulin sensitivity via action on adipocytes. Unfortunately, TZDs also degrade bone by inhibiting osteoblasts. An extract of Artemisia dracunculus L., termed PMI5011, improves blood glucose and insulin sensitivity via skeletal muscle, rather than fat, and may therefore spare bone. [...] Read more.
Thiazolidinediones (TZD) significantly improve insulin sensitivity via action on adipocytes. Unfortunately, TZDs also degrade bone by inhibiting osteoblasts. An extract of Artemisia dracunculus L., termed PMI5011, improves blood glucose and insulin sensitivity via skeletal muscle, rather than fat, and may therefore spare bone. Here, we examine the effects of PMI5011 and an identified active compound within PMI5011 (2′,4′-dihydroxy-4-methoxydihydrochalcone, DMC-2) on pre-osteoblasts. We hypothesized that PMI5011 and DMC-2 will not inhibit osteogenesis. To test our hypothesis, MC3T3-E1 cells were induced in osteogenic media with and without PMI5011 or DMC-2. Cell lysates were probed for osteogenic gene expression and protein content and were stained for osteogenic endpoints. Neither compound had an effect on early stain outcomes for alkaline phosphatase or collagen. Contrary to our hypothesis, PMI5011 at 30 µg/mL significantly increases osteogenic gene expression as early as day 1. Further, osteogenic proteins and cell culture mineralization trend higher for PMI5011-treated wells. Treatment with DMC-2 at 1 µg/mL similarly increased osteogenic gene expression and significantly increased mineralization, although protein content did not trend higher. Our data suggest that PMI5011 and DMC-2 have the potential to promote bone health via improved osteoblast maturation and activity. Full article
Show Figures

Figure 1

18 pages, 2535 KiB  
Article
Safety, Tolerability, and Pharmacokinetics of β-Cryptoxanthin Supplementation in Healthy Women: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial
by Karen M. L. Tan, Jolene Chee, Kezlyn L. M. Lim, Maisie Ng, Min Gong, Jia Xu, Felicia Tin, Padmapriya Natarajan, Bee Lan Lee, Choon Nam Ong, Mya Thway Tint, Michelle Z. L. Kee, Falk Müller-Riemenschneider, Peter D. Gluckman, Michael J. Meaney, Mukkesh Kumar, Neerja Karnani, Johan G. Eriksson, Bindu Nandanan, Adrian Wyss and David Cameron-Smithadd Show full author list remove Hide full author list
Nutrients 2023, 15(10), 2325; https://doi.org/10.3390/nu15102325 - 16 May 2023
Cited by 2 | Viewed by 3011
Abstract
Background: β-cryptoxanthin is a dietary carotenoid for which there have been few studies on the safety and pharmacokinetics following daily oral supplementation. Methods: 90 healthy Asian women between 21 and 35 years were randomized into three groups: 3 and 6 mg/day oral β-cryptoxanthin, [...] Read more.
Background: β-cryptoxanthin is a dietary carotenoid for which there have been few studies on the safety and pharmacokinetics following daily oral supplementation. Methods: 90 healthy Asian women between 21 and 35 years were randomized into three groups: 3 and 6 mg/day oral β-cryptoxanthin, and placebo. At 2, 4, and 8 weeks of supplementation, plasma carotenoid levels were measured. The effects of β-cryptoxanthin on blood retinoid-dependent gene expression, mood, physical activity and sleep, metabolic parameters, and fecal microbial composition were investigated. Results: β-cryptoxanthin supplementation for 8 weeks (3 and 6 mg/day) was found to be safe and well tolerated. Plasma β-cryptoxanthin concentration was significantly higher in the 6 mg/day group (9.0 ± 4.1 µmol/L) compared to 3 mg/day group (6.0 ± 2.6 µmol/L) (p < 0.03), and placebo (0.4 ± 0.1 µmol/L) (p < 0.001) after 8 weeks. Plasma all-trans retinol, α-cryptoxanthin, α-carotene, β-carotene, lycopene, lutein, and zeaxanthin levels were not significantly changed. No effects were found on blood retinol-dependent gene expression, mood, physical activity and sleep, metabolic parameters, and fecal microbial composition. Conclusions: Oral β-cryptoxanthin supplementation over 8 weeks lead to high plasma concentrations of β-cryptoxanthin, with no impact on other carotenoids, and was well tolerated in healthy women. Full article
(This article belongs to the Section Nutrition in Women)
Show Figures

Figure 1

13 pages, 687 KiB  
Article
Systemic Inflammation Indices and Association with Prostate Cancer Survival in a Diverse Patient Cohort
by Maeve Bailey-Whyte, Tsion Z. Minas, Tiffany H. Dorsey, Cheryl J. Smith, Christopher A. Loffredo and Stefan Ambs
Cancers 2023, 15(6), 1869; https://doi.org/10.3390/cancers15061869 - 20 Mar 2023
Cited by 21 | Viewed by 3113
Abstract
There is a lack of investigations assessing the performance of systemic inflammation indices as outcome predictive tools in African Americans with prostate cancer. This study aims to assess the relationships between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation (SII), and systemic inflammation [...] Read more.
There is a lack of investigations assessing the performance of systemic inflammation indices as outcome predictive tools in African Americans with prostate cancer. This study aims to assess the relationships between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation (SII), and systemic inflammation response index (SIRI) with survival outcomes among 680 diverse men with prostate cancer. Routine blood results were collected from self-identified African American and European American patients. We applied multivariable Cox regression modeling to examine the associations of systemic inflammation indices with overall and prostate cancer-specific survival. The median survival follow-up was 5.9 years, with 194 deaths. NLR, SII, and SIRI, but not PLR, showed associations with all-cause and prostate cancer-specific mortality when coded as dichotomized and continuous variables. NLR and SIRI were significantly associated with prostate cancer-specific mortality among all men (hazard ratio (HR) 2.56 for high vs. low NLR; HR 3.24 for high vs. low SIRI) and African American men (HR 2.96 for high vs. low NLR; HR 3.19 for high vs. low SIRI). Among European Americans, only SII showed an association with prostate cancer-specific survival. These observations suggest that inflammation indices merit further study as predictors of prostate cancer mortality. Full article
(This article belongs to the Section Cancer Epidemiology and Prevention)
Show Figures

Figure 1

10 pages, 1386 KiB  
Article
Genomic Characterization of a Relative of Mumps Virus in Lesser Dawn Bats of Southeast Asia
by Adrian C. Paskey, Xiao Fang Lim, Justin H. J. Ng, Gregory K. Rice, Wan Ni Chia, Casandra W. Philipson, Randy Foo, Regina Z. Cer, Kyle A. Long, Matthew R. Lueder, Lindsay Glang, Kenneth G. Frey, Theron Hamilton, Ian H. Mendenhall, Gavin J. Smith, Danielle E. Anderson, Lin-Fa Wang and Kimberly A. Bishop-Lilly
Viruses 2023, 15(3), 659; https://doi.org/10.3390/v15030659 - 28 Feb 2023
Cited by 2 | Viewed by 2700
Abstract
The importance of genomic surveillance on emerging diseases continues to be highlighted with the ongoing SARS-CoV-2 pandemic. Here, we present an analysis of a new bat-borne mumps virus (MuV) in a captive colony of lesser dawn bats (Eonycteris spelaea). This report [...] Read more.
The importance of genomic surveillance on emerging diseases continues to be highlighted with the ongoing SARS-CoV-2 pandemic. Here, we present an analysis of a new bat-borne mumps virus (MuV) in a captive colony of lesser dawn bats (Eonycteris spelaea). This report describes an investigation of MuV-specific data originally collected as part of a longitudinal virome study of apparently healthy, captive lesser dawn bats in Southeast Asia (BioProject ID PRJNA561193) which was the first report of a MuV-like virus, named dawn bat paramyxovirus (DbPV), in bats outside of Africa. More in-depth analysis of these original RNA sequences in the current report reveals that the new DbPV genome shares only 86% amino acid identity with the RNA-dependent RNA polymerase of its closest relative, the African bat-borne mumps virus (AbMuV). While there is no obvious immediate cause for concern, it is important to continue investigating and monitoring bat-borne MuVs to determine the risk of human infection. Full article
(This article belongs to the Special Issue Bat-Borne Viruses Research)
Show Figures

Figure 1

18 pages, 2593 KiB  
Article
Selective Transcription Factor Blockade Reduces Human Retinal Endothelial Cell Expression of Intercellular Adhesion Molecule-1 and Leukocyte Binding
by Yuefang Ma, Liam M. Ashander, Binoy Appukuttan, Feargal J. Ryan, Alwin C. R. Tan, Janet M. Matthews, Michael Z. Michael, David J. Lynn and Justine R. Smith
Int. J. Mol. Sci. 2023, 24(4), 3304; https://doi.org/10.3390/ijms24043304 - 7 Feb 2023
Cited by 5 | Viewed by 3012
Abstract
The interaction between leukocytes and cytokine-activated retinal endothelium is an initiating step in non-infectious uveitis involving the posterior eye, mediated by cell adhesion molecules. However, because cell adhesion molecules are required for immune surveillance, therapeutic interventions would ideally be employed indirectly. Using 28 [...] Read more.
The interaction between leukocytes and cytokine-activated retinal endothelium is an initiating step in non-infectious uveitis involving the posterior eye, mediated by cell adhesion molecules. However, because cell adhesion molecules are required for immune surveillance, therapeutic interventions would ideally be employed indirectly. Using 28 primary human retinal endothelial cell isolates, this study sought to identify transcription factor targets for reducing levels of the key retinal endothelial cell adhesion molecule, intercellular adhesion molecule (ICAM)-1, and limiting leukocyte binding to the retinal endothelium. Five candidate transcription factors—C2CD4B, EGR3, FOSB, IRF1, and JUNB—were identified by differential expression analysis of a transcriptome generated from IL-1β- or TNF-α-stimulated human retinal endothelial cells, interpreted in the context of the published literature. Further filtering involved molecular studies: of the five candidates, C2CD4B and IRF1 consistently demonstrated extended induction in IL-1β- or TNF-α-activated retinal endothelial cells and demonstrated a significant decrease in both ICAM-1 transcript and ICAM-1 membrane-bound protein expression by cytokine-activated retinal endothelial cells following treatment with small interfering RNA. RNA interference of C2CD4B or IRF1 significantly reduced leukocyte binding in a majority of human retinal endothelial cell isolates stimulated by IL-1β or TNF-α. Our observations suggest that the transcription factors C2CD4B and IRF1 may be potential drug targets for limiting leukocyte–retinal endothelial cell interactions in non-infectious uveitis involving the posterior eye. Full article
(This article belongs to the Special Issue Advances on Retinal Diseases)
Show Figures

Figure 1

250 pages, 84542 KiB  
Article
Deep Underground Neutrino Experiment (DUNE) Near Detector Conceptual Design Report
by A. Abed Abud, B. Abi, R. Acciarri, M. A. Acero, G. Adamov, D. Adams, M. Adinolfi, A. Aduszkiewicz, Z. Ahmad, J. Ahmed, T. Alion, S. Alonso Monsalve, M. Alrashed, C. Alt, A. Alton, P. Amedo, J. Anderson, C. Andreopoulos, M. P. Andrews, F. Andrianala, S. Andringa, N. Anfimov, A. Ankowski, M. Antonova, S. Antusch, A. Aranda-Fernandez, A. Ariga, L. O. Arnold, M. A. Arroyave, J. Asaadi, A. Aurisano, V. Aushev, D. Autiero, M. Ayala-Torres, F. Azfar, A. Back, H. Back, J. J. Back, C. Backhouse, P. Baesso, I. Bagaturia, L. Bagby, S. Balasubramanian, P. Baldi, B. Baller, B. Bambah, F. Barao, G. Barenboim, G. J. Barker, W. Barkhouse, C. Barnes, G. Barr, J. Barranco Monarca, N. Barros, J. L. Barrow, A. Basharina-Freshville, A. Bashyal, V. Basque, E. Belchior, J. B. R. Battat, F. Battisti, F. Bay, J. L. Bazo Alba, J. F. Beacom, E. Bechetoille, B. Behera, L. Bellantoni, G. Bellettini, V. Bellini, O. Beltramello, D. Belver, N. Benekos, F. Bento Neves, S. Berkman, P. Bernardini, R. M. Berner, H. Berns, S. Bertolucci, M. Betancourt, A. Betancur Rodríguez, M. Bhattacharjee, S. Bhuller, B. Bhuyan, S. Biagi, J. Bian, M. Biassoni, K. Biery, B. Bilki, M. Bishai, A. Bitadze, A. Blake, F. D. M. Blaszczyk, G. C. Blazey, E. Blucher, J. Boissevain, S. Bolognesi, T. Bolton, L. Bomben, M. Bonesini, M. Bongrand, F. Bonini, A. Booth, C. Booth, S. Bordoni, A. Borkum, T. Boschi, N. Bostan, P. Bour, C. Bourgeois, S. B. Boyd, D. Boyden, J. Bracinik, D. Braga, D. Brailsford, A. Brandt, J. Bremer, C. Brew, E. Brianne, S. J. Brice, C. Brizzolari, C. Bromberg, G. Brooijmans, J. Brooke, A. Bross, G. Brunetti, M. Brunetti, N. Buchanan, H. Budd, I. Cagnoli, D. Caiulo, P. Calafiura, J. Calcutt, M. Calin, S. Calvez, E. Calvo, A. Caminata, M. Campanelli, K. Cankocak, D. Caratelli, G. Carini, B. Carlus, P. Carniti, I. Caro Terrazas, H. Carranza, T. Carroll, J. F. Castaño Forero, A. Castillo, C. Castromonte, E. Catano-Mur, C. Cattadori, F. Cavalier, F. Cavanna, S. Centro, G. Cerati, A. Cervelli, A. Cervera Villanueva, M. Chalifour, A. Chappell, E. Chardonnet, N. Charitonidis, A. Chatterjee, S. Chattopadhyay, H. Chen, M. Chen, Y. Chen, Z. Chen, D. Cherdack, C. Chi, S. Childress, A. Chiriacescu, G. Chisnall, K. Cho, S. Choate, D. Chokheli, S. Choubey, A. Christensen, D. Christian, G. Christodoulou, A. Chukanov, E. Church, V. Cicero, P. Clarke, T. E. Coan, A. G. Cocco, J. A. B. Coelho, E. Conley, R. Conley, J. M. Conrad, M. Convery, S. Copello, L. Corwin, L. Cremaldi, L. Cremonesi, J. I. Crespo-Anadón, E. Cristaldo, R. Cross, A. Cudd, C. Cuesta, Y. Cui, D. Cussans, M. Dabrowski, O. Dalager, H. da Motta, L. Da Silva Peres, C. David, Q. David, G. S. Davies, S. Davini, J. Dawson, K. De, R. M. De Almeida, P. Debbins, I. De Bonis, M. P. Decowski, A. de Gouvêa, P. C. De Holanda, I. L. De Icaza Astiz, A. Deisting, P. De Jong, A. Delbart, D. Delepine, M. Delgado, A. Dell’Acqua, P. De Lurgio, J. R. T. de Mello Neto, D. M. DeMuth, S. Dennis, C. Densham, G. W. Deptuch, A. De Roeck, V. De Romeri, G. De Souza, R. Dharmapalan, F. Diaz, J. S. Díaz, S. Di Domizio, L. Di Giulio, P. Ding, L. Di Noto, C. Distefano, R. Diurba, M. Diwan, Z. Djurcic, N. Dokania, S. Dolan, M. J. Dolinski, L. Domine, D. Douglas, D. Douillet, G. Drake, F. Drielsma, D. Duchesneau, K. Duffy, P. Dunne, T. Durkin, H. Duyang, O. Dvornikov, D. A. Dwyer, A. S. Dyshkant, M. Eads, A. Earle, D. Edmunds, J. Eisch, L. Emberger, S. Emery, A. Ereditato, C. O. Escobar, G. Eurin, J. J. Evans, E. Ewart, A. C. Ezeribe, K. Fahey, A. Falcone, C. Farnese, Y. Farzan, J. Felix, M. Fernandes Carneiro da Silva, E. Fernandez-Martinez, P. Fernandez Menendez, F. Ferraro, L. Fields, F. Filthaut, A. Fiorentini, R. S. Fitzpatrick, W. Flanagan, B. Fleming, R. Flight, D. V. Forero, J. Fowler, W. Fox, J. Franc, K. Francis, D. Franco, J. Freeman, J. Freestone, J. Fried, A. Friedland, S. Fuess, I. Furic, A. P. Furmanski, A. Gabrielli, A. Gago, H. Gallagher, A. Gallas, A. Gallego-Ros, N. Gallice, V. Galymov, E. Gamberini, T. Gamble, R. Gandhi, R. Gandrajula, F. Gao, S. Gao, D. Garcia-Gamez, M. Á. García-Peris, S. Gardiner, D. Gastler, G. Ge, B. Gelli, A. Gendotti, S. Gent, Z. Ghorbani-Moghaddam, D. Gibin, I. Gil-Botella, S. Gilligan, C. Girerd, A. K. Giri, D. Gnani, O. Gogota, M. Gold, S. Gollapinni, K. Gollwitzer, R. A. Gomes, L. V. Gomez Bermeo, L. S. Gomez Fajardo, F. Gonnella, J. A. Gonzalez-Cuevas, D. Gonzalez-Diaz, M. Gonzalez-Lopez, M. C. Goodman, O. Goodwin, S. Goswami, C. Gotti, E. Goudzovski, C. Grace, M. Graham, R. Gran, E. Granados, P. Granger, A. Grant, C. Grant, D. Gratieri, P. Green, L. Greenler, J. Greer, W. C. Griffith, M. Groh, J. Grudzinski, K. Grzelak, W. Gu, V. Guarino, R. Guenette, E. Guerard, M. Guerzoni, A. Guglielmi, B. Guo, K. K. Guthikonda, R. Gutierrez, P. Guzowski, M. M. Guzzo, S. Gwon, A. Habig, H. Hadavand, R. Haenni, A. Hahn, J. Haiston, P. Hamacher-Baumann, T. Hamernik, P. Hamilton, J. Han, D. A. Harris, J. Hartnell, J. Harton, T. Hasegawa, C. Hasnip, R. Hatcher, K. W. Hatfield, A. Hatzikoutelis, C. Hayes, E. Hazen, A. Heavey, K. M. Heeger, J. Heise, K. Hennessy, S. Henry, M. A. Hernandez Morquecho, K. Herner, L. Hertel, J. Hewes, A. Higuera, T. Hill, S. J. Hillier, A. Himmel, J. Hoff, C. Hohl, A. Holin, E. Hoppe, G. A. Horton-Smith, M. Hostert, A. Hourlier, B. Howard, R. Howell, J. Huang, J. Huang, J. Hugon, G. Iles, N. Ilic, A. M. Iliescu, R. Illingworth, G. Ingratta, A. Ioannisian, L. Isenhower, R. Itay, A. Izmaylov, S. Jackson, V. Jain, E. James, B. Jargowsky, F. Jediny, D. Jena, Y. S. Jeong, C. Jesús-Valls, X. Ji, L. Jiang, S. Jiménez, A. Jipa, R. Johnson, N. Johnston, B. Jones, S. B. Jones, M. Judah, C. K. Jung, T. Junk, Y. Jwa, M. Kabirnezhad, A. Kaboth, I. Kadenko, I. Kakorin, F. Kamiya, N. Kaneshige, G. Karagiorgi, G. Karaman, A. Karcher, M. Karolak, Y. Karyotakis, S. Kasai, S. P. Kasetti, L. Kashur, N. Kazaryan, E. Kearns, P. Keener, K. J. Kelly, E. Kemp, O. Kemularia, W. Ketchum, S. H. Kettell, M. Khabibullin, A. Khotjantsev, A. Khvedelidze, D. Kim, B. King, B. Kirby, M. Kirby, J. Klein, K. Koehler, L. W. Koerner, S. Kohn, P. P. Koller, L. Kolupaeva, M. Kordosky, T. Kosc, U. Kose, V. A. Kostelecký, K. Kothekar, F. Krennrich, I. Kreslo, Y. Kudenko, V. A. Kudryavtsev, S. Kulagin, J. Kumar, P. Kumar, R. Kumar, P. Kunze, N. Kurita, C. Kuruppu, V. Kus, T. Kutter, A. Lambert, B. Land, K. Lande, C. E. Lane, K. Lang, T. Langford, J. Larkin, P. Lasorak, D. Last, C. Lastoria, A. Laundrie, G. Laurenti, A. Lawrence, I. Lazanu, R. LaZur, T. Le, S. Leardini, J. Learned, P. LeBrun, T. LeCompte, G. Lehmann Miotto, R. Lehnert, M. A. Leigui de Oliveira, M. Leitner, L. Li, S. W. Li, T. Li, Y. Li, H. Liao, C. S. Lin, Q. Lin, S. Lin, A. Lister, B. R. Littlejohn, J. Liu, S. Lockwitz, T. Loew, M. Lokajicek, I. Lomidze, K. Long, K. Loo, D. Lorca, T. Lord, J. M. LoSecco, W. C. Louis, X. G. Lu, K. B. Luk, X. Luo, N. Lurkin, T. Lux, V. P. Luzio, D. MacFarlane, A. A. Machado, P. Machado, C. T. Macias, J. R. Macier, A. Maddalena, A. Madera, P. Madigan, S. Magill, K. Mahn, A. Maio, A. Major, J. A. Maloney, G. Mandrioli, R. C. Mandujano, J. Maneira, L. Manenti, S. Manly, A. Mann, K. Manolopoulos, M. Manrique Plata, V. N. Manyam, L. Manzanillas, M. Marchan, A. Marchionni, W. Marciano, D. Marfatia, C. Mariani, J. Maricic, R. Marie, F. Marinho, A. D. Marino, D. Marsden, M. Marshak, C. M. Marshall, J. Marshall, J. Marteau, J. Martin-Albo, N. Martinez, D. A. Martinez Caicedo, S. Martynenko, K. Mason, A. Mastbaum, M. Masud, S. Matsuno, J. Matthews, C. Mauger, N. Mauri, K. Mavrokoridis, I. Mawby, R. Mazza, A. Mazzacane, E. Mazzucato, T. McAskill, E. McCluskey, N. McConkey, K. S. McFarland, C. McGrew, A. McNab, A. Mefodiev, P. Mehta, P. Melas, O. Mena, S. Menary, H. Mendez, D. P. Méndez, A. Menegolli, G. Meng, M. D. Messier, W. Metcalf, T. Mettler, M. Mewes, H. Meyer, T. Miao, G. Michna, T. Miedema, J. Migenda, V. Mikola, R. Milincic, W. Miller, J. Mills, C. Milne, O. Mineev, O. G. Miranda, S. Miryala, C. S. Mishra, S. R. Mishra, A. Mislivec, D. Mladenov, I. Mocioiu, K. Moffat, N. Moggi, R. Mohanta, T. A. Mohayai, N. Mokhov, J. Molina, L. Molina Bueno, A. Montanari, C. Montanari, D. Montanari, E. Montagna, L. M. Montano Zetina, J. Moon, M. Mooney, A. F. Moor, D. Moreno, C. Morris, C. Mossey, E. Motuk, C. A. Moura, J. Mousseau, W. Mu, L. Mualem, J. Mueller, M. Muether, S. Mufson, F. Muheim, A. Muir, M. Mulhearn, D. Munford, H. Muramatsu, S. Murphy, J. Musser, J. Nachtman, S. Nagu, M. Nalbandyan, R. Nandakumar, D. Naples, S. Narita, D. Navas-Nicolás, A. Navrer-Agasson, N. Nayak, M. Nebot-Guinot, K. Negishi, J. K. Nelson, J. Nesbit, M. Nessi, D. Newbold, M. Newcomer, D. Newhart, H. Newton, M. Niccolo, R. Nichol, F. Nicolas-Arnaldos, M. Nicoletta, E. Niner, K. Nishimura, A. Norman, A. Norrick, R. Northrop, P. Novella, J. A. Nowak, M. Oberling, J. P. Ochoa-Ricoux, A. Olivares Del Campo, A. Olivier, A. Olshevskiy, Y. Onel, Y. Onishchuk, J. Ott, L. Pagani, S. Pakvasa, G. Palacio, O. Palamara, S. Palestini, J. M. Paley, M. Pallavicini, C. Palomares, J. L. Palomino-Gallo, E. Pantic, V. Paolone, V. Papadimitriou, R. Papaleo, A. Papanestis, S. Paramesvaran, S. Parke, Z. Parsa, M. Parvu, S. Pascoli, L. Pasqualini, J. Pasternak, J. Pater, C. Patrick, L. Patrizii, R. B. Patterson, S. J. Patton, T. Patzak, A. Paudel, B. Paulos, L. Paulucci, Z. Pavlovic, G. Pawloski, D. Payne, V. Pec, S. J. M. Peeters, E. Pennacchio, A. Penzo, O. L. G. Peres, J. Perry, D. Pershey, G. Pessina, G. Petrillo, C. Petta, R. Petti, F. Piastra, L. Pickering, F. Pietropaolo, R. Plunkett, R. Poling, X. Pons, N. Poonthottathil, F. Poppi, S. Pordes, J. Porter, M. Potekhin, R. Potenza, B. V. K. S. Potukuchi, J. Pozimski, M. Pozzato, S. Prakash, T. Prakash, S. Prince, D. Pugnere, X. Qian, M. C. Queiroga Bazetto, J. L. Raaf, V. Radeka, J. Rademacker, B. Radics, A. Rafique, E. Raguzin, M. Rai, M. Rajaoalisoa, I. Rakhno, A. Rakotonandrasana, L. Rakotondravohitra, Y. A. Ramachers, R. Rameika, M. A. Ramirez Delgado, B. Ramson, A. Rappoldi, G. Raselli, P. Ratoff, S. Raut, R. F. Razakamiandra, J. S. Real, B. Rebel, M. Reggiani-Guzzo, T. Rehak, J. Reichenbacher, S. D. Reitzner, H. Rejeb Sfar, A. Renshaw, S. Rescia, F. Resnati, A. Reynolds, C. Riccio, G. Riccobene, L. C. J. Rice, J. Ricol, A. Rigamonti, Y. Rigaut, D. Rivera, L. Rochester, M. Roda, P. Rodrigues, M. J. Rodriguez Alonso, E. Rodriguez Bonilla, J. Rodriguez Rondon, S. Rosauro-Alcaraz, M. Rosenberg, P. Rosier, B. Roskovec, M. Rossella, J. Rout, P. Roy, S. Roy, A. Rubbia, C. Rubbia, F. C. Rubio, B. Russell, D. Ruterbories, R. Saakyan, S. Sacerdoti, T. Safford, R. Sahay, N. Sahu, P. Sala, N. Samios, O. Samoylov, M. C. Sanchez, D. A. Sanders, D. Sankey, S. Santana, M. Santos-Maldonado, N. Saoulidou, P. Sapienza, C. Sarasty, I. Sarcevic, G. Savage, V. Savinov, A. Scaramelli, A. Scarff, A. Scarpelli, T. Schaffer, H. Schellman, P. Schlabach, D. Schmitz, K. Scholberg, A. Schukraft, E. Segreto, J. Sensenig, I. Seong, A. Sergi, D. Sgalaberna, M. H. Shaevitz, S. Shafaq, M. Shamma, R. Sharankova, H. R. Sharma, R. Sharma, T. Shaw, C. Shepherd-Themistocleous, S. Shin, D. Shooltz, R. Shrock, L. Simard, F. Simon, N. Simos, J. Sinclair, G. Sinev, J. Singh, J. Singh, V. Singh, R. Sipos, F. W. Sippach, G. Sirri, A. Sitraka, K. Siyeon, K. Skarpaas VIII, A. Smith, E. Smith, P. Smith, J. Smolik, M. Smy, E. L. Snider, P. Snopok, M. Soares Nunes, H. Sobel, M. Soderberg, C. J. Solano Salinas, S. Söldner-Rembold, S. Soleti, N. Solomey, V. Solovov, W. E. Sondheim, M. Sorel, J. Soto-Oton, A. Sousa, K. Soustruznik, F. Spagliardi, M. Spanu, J. Spitz, N. J. C. Spooner, K. Spurgeon, R. Staley, M. Stancari, L. Stanco, R. Stanley, R. Stein, H. M. Steiner, J. Stewart, B. Stillwell, J. Stock, F. Stocker, T. Stokes, M. Strait, T. Strauss, S. Striganov, A. Stuart, J. G. Suarez, H. Sullivan, D. Summers, A. Surdo, V. Susic, L. Suter, C. M. Sutera, R. Svoboda, B. Szczerbinska, A. M. Szelc, R. Talaga, H. A. Tanaka, B. Tapia Oregui, A. Tapper, S. Tariq, E. Tatar, R. Tayloe, A. M. Teklu, M. Tenti, K. Terao, C. A. Ternes, F. Terranova, G. Testera, A. Thea, J. L. Thompson, C. Thorn, S. C. Timm, J. Todd, A. Tonazzo, D. Torbunov, M. Torti, M. Tortola, F. Tortorici, D. Totani, M. Toups, C. Touramanis, N. Tosi, R. Travaglini, J. Trevor, S. Trilov, W. H. Trzaska, Y. T. Tsai, Z. Tsamalaidze, K. V. Tsang, N. Tsverava, S. Tufanli, C. Tull, E. Tyley, M. Tzanov, M. A. Uchida, J. Urheim, T. Usher, S. Uzunyan, M. R. Vagins, P. Vahle, G. A. Valdiviesso, E. Valencia, P. Valerio, Z. Vallari, J. W. F. Valle, S. Vallecorsa, R. Van Berg, R. G. Van de Water, F. Varanini, D. Vargas, G. Varner, J. Vasel, S. Vasina, G. Vasseur, N. Vaughan, K. Vaziri, S. Ventura, A. Verdugo, S. Vergani, M. A. Vermeulen, M. Verzocchi, M. Vicenzi, H. Vieira de Souza, C. Vignoli, C. Vilela, B. Viren, T. Vrba, T. Wachala, A. V. Waldron, M. Wallbank, H. Wang, J. Wang, L. Wang, M. H. L. S. Wang, Y. Wang, Y. Wang, K. Warburton, D. Warner, M. Wascko, D. Waters, A. Watson, P. Weatherly, A. Weber, M. Weber, H. Wei, A. Weinstein, D. Wenman, M. Wetstein, A. White, L. H. Whitehead, D. Whittington, M. J. Wilking, C. Wilkinson, Z. Williams, F. Wilson, R. J. Wilson, J. Wolcott, T. Wongjirad, A. Wood, K. Wood, E. Worcester, M. Worcester, C. Wret, W. Wu, W. Wu, Y. Xiao, E. Yandel, G. Yang, K. Yang, S. Yang, T. Yang, A. Yankelevich, N. Yershov, K. Yonehara, T. Young, B. Yu, H. Yu, J. Yu, W. Yuan, R. Zaki, J. Zalesak, L. Zambelli, B. Zamorano, A. Zani, L. Zazueta, G. Zeit, G. P. Zeller, J. Zennamo, K. Zeug, C. Zhang, M. Zhao, E. Zhivun, G. Zhu, P. Zilberman, E. D. Zimmerman, M. Zito, S. Zucchelli, J. Zuklin, V. Zutshi, R. Zwaska and On behalf of the DUNE Collaborationadd Show full author list remove Hide full author list
Instruments 2021, 5(4), 31; https://doi.org/10.3390/instruments5040031 - 29 Sep 2021
Cited by 131 | Viewed by 18093
Abstract
The Deep Underground Neutrino Experiment (DUNE) is an international, world-class experiment aimed at exploring fundamental questions about the universe that are at the forefront of astrophysics and particle physics research. DUNE will study questions pertaining to the preponderance of matter over antimatter in [...] Read more.
The Deep Underground Neutrino Experiment (DUNE) is an international, world-class experiment aimed at exploring fundamental questions about the universe that are at the forefront of astrophysics and particle physics research. DUNE will study questions pertaining to the preponderance of matter over antimatter in the early universe, the dynamics of supernovae, the subtleties of neutrino interaction physics, and a number of beyond the Standard Model topics accessible in a powerful neutrino beam. A critical component of the DUNE physics program involves the study of changes in a powerful beam of neutrinos, i.e., neutrino oscillations, as the neutrinos propagate a long distance. The experiment consists of a near detector, sited close to the source of the beam, and a far detector, sited along the beam at a large distance. This document, the DUNE Near Detector Conceptual Design Report (CDR), describes the design of the DUNE near detector and the science program that drives the design and technology choices. The goals and requirements underlying the design, along with projected performance are given. It serves as a starting point for a more detailed design that will be described in future documents. Full article
Show Figures

Figure 1

11 pages, 560 KiB  
Article
Urinary PGE-M in Men with Prostate Cancer
by Maeve Kiely, Ginger L. Milne, Tsion Z. Minas, Tiffany H. Dorsey, Wei Tang, Cheryl J. Smith, Francine Baker, Christopher A. Loffredo, Clayton Yates, Michael B. Cook and Stefan Ambs
Cancers 2021, 13(16), 4073; https://doi.org/10.3390/cancers13164073 - 13 Aug 2021
Cited by 6 | Viewed by 2753
Abstract
Urinary PGE-M is a stable metabolite of prostaglandin E2 (PGE2). PGE2 is a product of the inflammatory COX signaling pathway and has been associated with cancer incidence and metastasis. Its synthesis can be inhibited by aspirin. We investigated the association of PGE-M with [...] Read more.
Urinary PGE-M is a stable metabolite of prostaglandin E2 (PGE2). PGE2 is a product of the inflammatory COX signaling pathway and has been associated with cancer incidence and metastasis. Its synthesis can be inhibited by aspirin. We investigated the association of PGE-M with lethal prostate cancer in a case–control study of African American (AA) and European American men. We measured urinary PGE-M using mass-spectrometry. Samples were obtained from 977 cases and 1022 controls at the time of recruitment. We applied multivariable logistic and Cox regression modeling to examine associations of PGE-M with prostate cancer and participant survival. Median survival follow-up was 8.4 years, with 246 deaths among cases. Self-reported aspirin use over the past 5 years was assessed with a questionnaire. Race/ethnicity was self-reported. Urinary PGE-M levels did not differ between men with prostate cancer and population-based controls. We observed no association between PGE-M and aggressive disease nor prostate-cancer-specific survival. However, we observed a statistically significant association between higher (>median) PGE-M and all-cause mortality in AA cases who did not regularly use aspirin (HR = 2.04, 95% CI 1.23–3.37). Among cases who reported using aspirin, there was no association. Our study does not support a meaningful association between urinary PGE-M and prostate cancer. Moreover, PGE-M levels were not associated with aggressive prostate cancer. However, the observed association between elevated PGE-M and all-cause mortality in AA non-aspirin users reinforces the potential benefit of aspirin to reduce mortality among AA men with prostate cancer. Full article
(This article belongs to the Section Cancer Epidemiology and Prevention)
Show Figures

Graphical abstract

24 pages, 7475 KiB  
Article
Environmentally Relevant Iron Oxide Nanoparticles Produce Limited Acute Pulmonary Effects in Rats at Realistic Exposure Levels
by Chang Guo, Ralf J. M. Weber, Alison Buckley, Julie Mazzolini, Sarah Robertson, Juana Maria Delgado-Saborit, Joshua Z. Rappoport, James Warren, Alan Hodgson, Paul Sanderson, James Kevin Chipman, Mark R. Viant and Rachel Smith
Int. J. Mol. Sci. 2021, 22(2), 556; https://doi.org/10.3390/ijms22020556 - 8 Jan 2021
Cited by 19 | Viewed by 4349
Abstract
Iron is typically the dominant metal in the ultrafine fraction of airborne particulate matter. Various studies have investigated the toxicity of inhaled nano-sized iron oxide particles (FeOxNPs) but their results have been contradictory, with some indicating no or minor effects and [...] Read more.
Iron is typically the dominant metal in the ultrafine fraction of airborne particulate matter. Various studies have investigated the toxicity of inhaled nano-sized iron oxide particles (FeOxNPs) but their results have been contradictory, with some indicating no or minor effects and others finding effects including oxidative stress and inflammation. Most studies, however, did not use materials reflecting the characteristics of FeOxNPs present in the environment. We, therefore, analysed the potential toxicity of FeOxNPs of different forms (Fe3O4, α-Fe2O3 and γ-Fe2O3) reflecting the characteristics of high iron content nano-sized particles sampled from the environment, both individually and in a mixture (FeOx-mix). A preliminary in vitro study indicated Fe3O4 and FeOx-mix were more cytotoxic than either form of Fe2O3 in human bronchial epithelial cells (BEAS-2B). Follow-up in vitro (0.003, 0.03, 0.3 µg/mL, 24 h) and in vivo (Sprague–Dawley rats, nose-only exposure, 50 µg/m3 and 500 µg/m3, 3 h/d × 3 d) studies therefore focused on these materials. Experiments in vitro explored responses at the molecular level via multi-omics analyses at concentrations below those at which significant cytotoxicity was evident to avoid detection of responses secondary to toxicity. Inhalation experiments used aerosol concentrations chosen to produce similar levels of particle deposition on the airway surface as were delivered in vitro. These were markedly higher than environmental concentrations. No clinical signs of toxicity were seen nor effects on BALF cell counts or LDH levels. There were also no significant changes in transcriptomic or metabolomic responses in lung or BEAS-2B cells to suggest adverse effects. Full article
(This article belongs to the Special Issue Toxicology of Metal NPs and OTC)
Show Figures

Figure 1

45 pages, 1157 KiB  
Article
A Decade with VAMDC: Results and Ambitions
by Damien Albert, Bobby K. Antony, Yaye Awa Ba, Yuri L. Babikov, Philippe Bollard, Vincent Boudon, Franck Delahaye, Giulio Del Zanna, Milan S. Dimitrijević, Brian J. Drouin, Marie-Lise Dubernet, Felix Duensing, Masahiko Emoto, Christian P. Endres, Alexandr Z. Fazliev, Jean-Michel Glorian, Iouli E. Gordon, Pierre Gratier, Christian Hill, Darko Jevremović, Christine Joblin, Duck-Hee Kwon, Roman V. Kochanov, Erumathadathil Krishnakumar, Giuseppe Leto, Petr A. Loboda, Anastasiya A. Lukashevskaya, Oleg M. Lyulin, Bratislav P. Marinković, Andrew Markwick, Thomas Marquart, Nigel J. Mason, Claudio Mendoza, Tom J. Millar, Nicolas Moreau, Serguei V. Morozov, Thomas Möller, Holger S. P. Müller, Giacomo Mulas, Izumi Murakami, Yury Pakhomov, Patrick Palmeri, Julien Penguen, Valery I. Perevalov, Nikolai Piskunov, Johannes Postler, Alexei I. Privezentsev, Pascal Quinet, Yuri Ralchenko, Yong-Joo Rhee, Cyril Richard, Guy Rixon, Laurence S. Rothman, Evelyne Roueff, Tatiana Ryabchikova, Sylvie Sahal-Bréchot, Paul Scheier, Peter Schilke, Stephan Schlemmer, Ken W. Smith, Bernard Schmitt, Igor Yu. Skobelev, Vladimir A. Srecković, Eric Stempels, Serguey A. Tashkun, Jonathan Tennyson, Vladimir G. Tyuterev, Charlotte Vastel, Veljko Vujčić, Valentine Wakelam, Nicholas A. Walton, Claude Zeippen and Carlo Maria Zwölfadd Show full author list remove Hide full author list
Atoms 2020, 8(4), 76; https://doi.org/10.3390/atoms8040076 - 21 Oct 2020
Cited by 85 | Viewed by 7755
Abstract
This paper presents an overview of the current status of the Virtual Atomic and Molecular Data Centre (VAMDC) e-infrastructure, including the current status of the VAMDC-connected (or to be connected) databases, updates on the latest technological development within the infrastructure and a presentation [...] Read more.
This paper presents an overview of the current status of the Virtual Atomic and Molecular Data Centre (VAMDC) e-infrastructure, including the current status of the VAMDC-connected (or to be connected) databases, updates on the latest technological development within the infrastructure and a presentation of some application tools that make use of the VAMDC e-infrastructure. We analyse the past 10 years of VAMDC development and operation, and assess their impact both on the field of atomic and molecular (A&M) physics itself and on heterogeneous data management in international cooperation. The highly sophisticated VAMDC infrastructure and the related databases developed over this long term make them a perfect resource of sustainable data for future applications in many fields of research. However, we also discuss the current limitations that prevent VAMDC from becoming the main publishing platform and the main source of A&M data for user communities, and present possible solutions under investigation by the consortium. Several user application examples are presented, illustrating the benefits of VAMDC in current research applications, which often need the A&M data from more than one database. Finally, we present our vision for the future of VAMDC. Full article
(This article belongs to the Special Issue Development and Perspectives of Atomic and Molecular Databases)
Show Figures

Figure 1

Back to TopTop